SCHEDULE 13G/A: BlackRock Discloses 7.6% Stake in 10x Genomics

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.6% of the common stock of 10x Genomics, Inc. as of June 30, 2025.

Summary

• BlackRock, Inc. beneficially owns 8,496,636 shares of 10x Genomics, Inc. common stock.
• This ownership represents 7.6% of the total outstanding common stock of 10x Genomics, Inc.
• BlackRock holds sole voting power over 8,275,651 shares and sole dispositive power over 8,496,636 shares.
• The filing is an Amendment No. 6 to the Schedule 13G, indicating ongoing disclosure of BlackRock's position.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without positive or negative implications for the company's performance or outlook.

Future Outlook

NA

Management Comments

• The securities referred to were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing reflects a routine disclosure by a major institutional asset manager, BlackRock, regarding its significant passive investment in a publicly traded biotechnology company, 10x Genomics, Inc. Such disclosures are standard for investors holding more than 5% of a company's shares and provide transparency into institutional ownership trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.

Key Dates

Keywords

10x Genomics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Ownership Disclosure